Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combination

by Nijhuis, Anke M. , Wickremesinghe, Chiharu , Xu, Yuewei , McKinney, Flora , Benito, Adrian , Tate, Edward W. , Keun, Hector C. , Tyson, Katie , Ma, Yurui , Siskos, Alexandros P. , Xu, Yitao , Balcells, Cristina , Bray, Chandler , McNeish, Iain A. , An, Lyutong , Babuta, Julia , Gruet, Michael , Spear, Sarah

in Cancer Biology

2024

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Do you wish to request the book?

RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combination

in Cancer Biology

2024

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Paper

RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combination

Nijhuis, Anke M.,

Wickremesinghe, Chiharu,

Xu, Yuewei,

McKinney, Flora,

Benito, Adrian,

Tate, Edward W.,

Keun, Hector C.,

Tyson, Katie,

Ma, Yurui,

Siskos, Alexandros P.,

Xu, Yitao,

Balcells, Cristina,

Bray, Chandler,

McNeish, Iain A.,

An, Lyutong,

Babuta, Julia,

Gruet, Michael,

Spear, Sarah

2024

Overview

The combination of PARP and NAMPT inhibitors (PARPi/NAMPTi) has been explored for the treatment of TNBC, Ewing Sarcoma and high grade serous carcinoma (HGSC). However, dose limiting toxicity has hampered NAMPTi in clinical trials. To maximise the therapeutic window, we set out to identify predictive genomic biomarkers. Bioinformatic analysis and screening of a panel of epithelial ovarian cancer (EOC) cell lines revealed that cells with RAS/PI3K pathway mutations were sensitive to the NAMPTi FK866. Activity of olaparib and FK866 was associated with a reduction in nicotinamide mononucleotide (NMN) and the PARP substrate nicotinamide adenine dinucleotide (NAD+), with coincident increases in ROS production, DNA damage and apoptosis induction. Caspase 3/7 activity was upregulated to a greater extent in RAS/PI3K mutant cell lines. Finally, the combination significantly reduced omental tumour weight and increased overall survival in mice injected with ID8 Trp53-/-;Pten-/- cells. This study highlights the potential of the PARPi/NAMPTi combination in RAS/PI3K pathway mutant EOC.

Share this book

Add to My Shelf

Publisher

Cold Spring Harbor Laboratory

Subject

Cancer Biology